The Efficacy of Brentuximab Vedotin in Relapsed/Refractory Classical Hodgkin’s Lymphoma and Quality of Life: Results of a Multi-Center Observational Prospective Study in the Context of Real Clinical Practice
| العنوان: | The Efficacy of Brentuximab Vedotin in Relapsed/Refractory Classical Hodgkin’s Lymphoma and Quality of Life: Results of a Multi-Center Observational Prospective Study in the Context of Real Clinical Practice |
|---|---|
| المؤلفون: | T.I. Ionova, A.A. Amdiev, M.I. Andrievskikh, E.A. Baryakh, E.V. Vasil’ev, M.V. Volkov, E.M. Volodicheva, V.V. Ivanov, O.V. Kaverina, K.D. Kaplanov, T.Yu. Klitochenko, V.I. Kurakin, D.G. Lazareva, O.G. Larionova, K.V. Lepik, I.B. Lysenko, V.Ya. Melnichenko, R.I. Minullina, O.V. Mironov, E.N. Misyurina, N.B. Mikhailova, N.E. Mochkin, Tatyana Pavlovna Nikitina, T.S. Petrova, N.M. Porfirieva, O.A. Rukavitsyn, A.A. Samoilova, R.N. Safin, P.I. Simashova, E.G. Smirnova, N.A. Trenina, N.V. Fadeeva, G.N. Khusainova, V.L. Chang, T.V. Shelekhova, D.G. Sherstnev |
| المصدر: | Clinical oncohematology. 15:42-53 |
| بيانات النشر: | Practical Medicine Publishing House, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Oncology, Hematology |
| الوصف: | Aim. To study the quality of life and symptoms, to assess the clinical effect and treatment safety in relapsed/refractory classical Hodgkin’s lymphoma (r/r cHL) patients treated with brentuximab vedotin (BV) as > 3rd-line therapy in the context of real clinical practice. Materials & Methods. The study enrolled 62 r/r cHL patients after the second- and subsequent-line chemotherapies, who are either ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) at the time of their enrollment into the study or after the failure of high-dose chemotherapy (HDCT) with auto-HSCT. The median age was 31 years; 46.8 % of patients were women. The patients received BV 1.8 mg/kg intravenously every 3 weeks. Clinical parameters, quality of life, and symptoms were assessed prior to BV therapy and in 3, 6, 9, 12, and 15 months after therapy onset. The RAND SF-36 form was used to assess the quality of life, and the ESAS-R tool was applied to report on symptoms. Results. Objective response was observed in 68.3 % of patients, 40 % out of them showed complete response. The median progression-free survival was 10.6 months (95% confidence interval 7.4-12.9 months). Safety profile corresponded to the published data. Adverse events of grade 3/4 were identified in 1.6 % of patients. In the period of 15 months after therapy onset, quality of life improvement or stabilization was reported based on all the scales of RAND SF-36 (GEE, p < 0.001), and symptom relief was shown based on ESAS-R total score (GEE, p < 0.001). Conclusion. In the context of real clinical practice, BV appeared to be effective in r/r cHL patients either after the second- or subsequent-line chemotherapies or after the failure of HDCT with auto-HSCT. The study demonstrated that BV was well tolerated by the patients. BV therapy contributes to the improvement of r/r cHL patients’ quality of life. Positive changes in quality of life and symptoms on BV therapy testify to its patient-assessed efficacy and safety. |
| تدمد: | 2500-2139 1997-6933 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::b5f5f1bcf196d11417b9e7a56260724d https://doi.org/10.21320/2500-2139-2022-15-1-42-53 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi...........b5f5f1bcf196d11417b9e7a56260724d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 25002139 19976933 |
|---|